As Traversa Files for Bankruptcy, Co-Founder Seeks Partnership for Delivery Technology | GenomeWeb

Traversa Therapeutics has filed for bankruptcy after failing to secure the financing it needed to continue advancing its core RNAi delivery technology, Gene Silencing News has learned.

However, a portion of that technology is now being shopped around by Traversa co-founder Scott Petersen, who is on the lookout for an industry partner interesting in bringing him on board to continue its development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.